Alamar Biosciences Inc. Common Stock (ALMR)
Stock · NASDAQ · Industrials
$25.28as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Resistance level
$32.42
Industry
Biotechnology: Laboratory Analytical Instruments
About ALMR
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiple…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 286
- Website
- alamarbio.com
Fundamentals
- 1-day range
- $25.11$28.35
- Market cap
- $1.95B
- P/E (trailing)
- —
- P/E (forward)
- -60.69
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- -0.79
- Avg. volume
- 446.8K
52-week range
$18.85$39.61
Next earnings: November 3, 2026 · EPS estimate $-0.19
Forecasts
5 analyst ratings
Buy 82%
Hold 18%
Sell 0%
1-year price forecast
High
$45
+78.0%
Median
$34
+34.5%
Low
$31
+22.6%
Alamar Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALMRAlamar Biosciences Inc. Common Stock$25.28▼ 7.80%Market cap $1.95BP/E —$18.85$39.61
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
- PACBPacific Biosciences of California Inc. Common Stock$1.73▼ 11.73%Market cap $361.85MP/E —$1.07$3.44
- LABStandard BioTools Inc. Common Stock$0.63▼ 4.55%Market cap $313.21MP/E 2.92$0.6251$1.72
- QTRXQuanterix Corporation Common Stock$2.87▼ 6.51%Market cap $180.42MP/E —$2.15$8.77
- SEERSeer Inc. Class A Common Stock$2.03▼ 0.49%Market cap $120.41MP/E —$1.55$2.41
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALMR Alamar Biosciences Inc. Common Stock | $1.95B | — | $25.28 | ▼ 7.80% | $18.85$39.61 |
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
| PACB Pacific Biosciences of California Inc. Common Stock | $361.85M | — | $1.73 | ▼ 11.73% | $1.07$3.44 |
| LAB Standard BioTools Inc. Common Stock | $313.21M | 2.92 | $0.63 | ▼ 4.55% | $0.6251$1.72 |
| QTRX Quanterix Corporation Common Stock | $180.42M | — | $2.87 | ▼ 6.51% | $2.15$8.77 |
| SEER Seer Inc. Class A Common Stock | $120.41M | — | $2.03 | ▼ 0.49% | $1.55$2.41 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026Yahoo · 10/8/2026
- Alamar: The Consumables Flywheel Is Just Getting StartedSeekingAlpha · 10/8/2026
- Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership TeamYahoo · 10/5/2026
- Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s TreatmentYahoo · 9/24/2026
- Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On FridayBenzinga · 9/18/2026
- Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
145.3K
Disposed
35.75M
- John L. Brottem · September 14, 2026 · Grant85.0K
- John L. Brottem · September 14, 2026 · Grant29.0K
- Robert P. Ragusa · September 1, 2026 · Grant25.6K
- Robert P. Ragusa · September 1, 2026 · Grant5.7K
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion4.65M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion3.88M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion4.22M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion113.6K
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion5.74M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion154.4K
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion6.40M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · Conversion172.3K
- Qiming Venture Partners VI, L.P. · April 20, 2026 · J1.92M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · J1.61M
- Qiming Venture Partners VI, L.P. · April 20, 2026 · J6.88M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Alamar Biosciences Sets Q3 2026 Earnings Release Date
Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.
Alamar Biosciences Sets Q3 2026 Earnings Release Date. Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.